Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study.
Parente, Alessandro Kamarajah, Sivesh K Baia, Marco Tirotta, Fabio Manzia, Tommaso M Hilal, Mohammed Abu Pawlik, Timothy M White, Steven A Dahdaleh, Fadi S
Parente, Alessandro
Kamarajah, Sivesh K
Baia, Marco
Tirotta, Fabio
Manzia, Tommaso M
Hilal, Mohammed Abu
Pawlik, Timothy M
White, Steven A
Dahdaleh, Fadi S
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-02-07
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
There were 9411 patients undergoing surgery for iCCA (n = 3772, 39.5%), hCCA (n = 1879, 20%), and dCCA (n = 3760, 40%). Of these, 10.6% (n = 399), 6.5% (n = 123), and 7.2% (n = 271) with iCCA, hCCA, and dCCA received NAC, respectively. On adjusted analyses, patients receiving NAC followed by surgery had significantly improved OS, compared to SA for iCCA (HR 0.75, CI95% 0.64-0.88, p < 0.001), hCCA (HR 0.72, CI95% 0.54-0.97, p = 0.033), and for dCCA (HR 0.65, CI95% 0.53-0.78, p < 0.001). However, sensitivity analyses demonstrated no differences in OS between NACs, followed by surgery or AC after surgery in iCCA (HR 1.19, CI95% 0.99-1.45, p = 0.068), hCCA (HR 0.83 CI95% 0.59-1.19, p = 0.311), and dCCA (HR 1.13 CI95% 0.91-1.41, p = 0.264).
Citation
Parente A, Kamarajah SK, Baia M, Tirotta F, Manzia TM, Hilal MA, Pawlik TM, White SA, Dahdaleh FS. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. J Gastrointest Surg. 2023 Apr;27(4):741-749. doi: 10.1007/s11605-023-05606-y. Epub 2023 Feb 7.
Type
Article